| Literature DB >> 27721827 |
Koshiro Nishimoto1, Tsugio Seki2, Yuichiro Hayashi3, Shuji Mikami3, Ghaith Al-Eyd2, Ken Nakagawa4, Shinya Morita5, Takeo Kosaka5, Mototsugu Oya5, Fumiko Mitani6, Makoto Suematsu6, Yasuaki Kabe6, Kuniaki Mukai7.
Abstract
Background. The immunohistochemical detection of aldosterone synthase (CYP11B2) and steroid 11β-hydroxylase (CYP11B1) has enabled the identification of aldosterone-producing cell clusters (APCCs) in the subcapsular portion of the human adult adrenal cortex. We hypothesized that adrenals have layered zonation in early postnatal stages and are remodeled to possess APCCs over time. Purposes. To investigate changes in human adrenocortical zonation with age. Methods. We retrospectively analyzed adrenal tissues prepared from 33 autopsied patients aged between 0 and 50 years. They were immunostained for CYP11B2 and CYP11B1. The percentage of APCC areas over the whole adrenal area (AA/WAA, %) and the number of APCCs (NOA, APCCs/mm2) were calculated by four examiners. Average values were used in statistical analyses. Results. Adrenals under 11 years old had layered zona glomerulosa (ZG) and zona fasciculata (ZF) without apparent APCCs. Some adrenals had an unstained (CYP11B2/CYP11B1-negative) layer between ZG and ZF, resembling the rat undifferentiated cell zone. Average AA/WAA and NOA correlated with age, suggesting that APCC development is associated with aging. Possible APCC-to-APA transitional lesions were incidentally identified in two adult adrenals. Conclusions. The adrenal cortex with layered zonation remodels to possess APCCs over time. APCC generation may be associated with hypertension in adults.Entities:
Year: 2016 PMID: 27721827 PMCID: PMC5046023 DOI: 10.1155/2016/7834356
Source DB: PubMed Journal: Int J Endocrinol ISSN: 1687-8337 Impact factor: 3.257
Patient characteristics, AA/WAA, and NOA/WAA.
| Case # | Section # | Age | Sex | Cause of death | AA/WAA (%) | NOA/WAA (APCCs/mm2) |
|---|---|---|---|---|---|---|
| 1 | A021 | 0.75 | F | Postliver transplantation | 0.000 ± 0.000 | 0.000 ± 0.000 |
| 2 | A022 | 1 | M | Heterotaxy syndrome | 0.000 ± 0.000 | 0.000 ± 0.000 |
| 3 | A023 | 1 | F | Brain tumor | 0.000 ± 0.000 | 0.000 ± 0.000 |
| 4 | A024 | 1.8 | M | Postliver transplantation | 0.000 ± 0.000 | 0.000 ± 0.000 |
| 5 | A025 | 2 | M | Acute lung dysfunction | 0.000 ± 0.000 | 0.000 ± 0.000 |
| 6 | A026 | 3 | F | Pulmonary dysfunction | 0.000 ± 0.000 | 0.000 ± 0.000 |
| 7 | A027 | 10 | M | Encephalopathy due to Reye's syndrome | 0.000 ± 0.000 | 0.000 ± 0.000 |
| 8 | A028 | 11 | F | Malignant peripheral nerve sheath tumors | 0.000 ± 0.000 | 0.000 ± 0.000 |
| 10 | A030 | 18 | M | Hemophagocytic syndrome | 0.042 ± 0.042 | 0.017 ± 0.017 |
| 12 | A032 | 19 | F | Postliver transplantation | 0.000 ± 0.000 | 0.000 ± 0.000 |
| 14 | A034 | 22 | F | Malignant intrapelvic tumor | 7.875 ± 1.410 | 0.685 ± 0.151 |
| 16 | A036 | 24 | F | Pulmonary hypertension | 1.871 ± 0.242 | 0.257 ± 0.049 |
| 19 | A039 | 28 | F | Pulmonary alveolar hemorrhage | 1.094 ± 0.284 | 0.096 ± 0.018 |
| 21 | A042 | 29 | M | Sepsis due to acute myelocytic leukemia | 0.315 ± 0.192 | 0.016 ± 0.016 |
| 22 | A043 | 29 | F | Subarachnoid hemorrhage | 0.000 ± 0.000 | 0.000 ± 0.000 |
| 23 | A044, A045 | 33 | M | Sepsis | 0.000 ± 0.000 | 0.000 ± 0.000 |
| 24 | A046 | 33 | M | Acute heart failure | 0.016 ± 0.016 | 0.015 ± 0.015 |
| 25 | A047 | 34 | M | Aorta stenosis | 0.865 ± 0.159 | 0.188 ± 0.044 |
| 27 | A049 | 38 | F | Sepsis | 1.568 ± 0.579 | 0.171 ± 0.047 |
| 28 | A050 | 38 | M | Liver cirrhosis | 5.156 ± 1.045 | 0.422 ± 0.068 |
| 29 | A051 | 39 | M | Myelodysplastic syndrome | 0.576 ± 0.046 | 0.117 ± 0.030 |
| 30 | A052 | 40 | F | Gastric cancer | 1.520 ± 0.399 | 0.171 ± 0.019 |
| 31 | A053 | 40 | F | Pulmonitis due to systemic lupus erythematosus | 0.104 ± 0.104 | 0.021 ± 0.021 |
| 32 | A054, A055 | 41 | F | Ovarian carcinoma | 2.250 ± 3.099 | 0.277 ± 0.088 |
| 36 | A059 | 44 | F | Renal cell carcinoma | 15.362 ± 3.400 | 0.449 ± 0.050 |
| 37 | A060 | 45 | M | Heart failure | 1.229 ± 0.194 | 0.274 ± 0.032 |
| 38 | A061 | 45 | M | Lung cancer | 1.771 ± 0.530 | 0.166 ± 0.047 |
| 40 | A063 | 45 | M | Hepatic failure due to liver cancer | 6.197 ± 0.996 | 0.672 ± 0.134 |
| 42 | A065 | 45 | M | Heart failure | 5.587 ± 2.451 | 0.563 ± 0.232 |
| 43 | A066 | 47 | M | Bronchiectasis | 6.022 ± 1.113 | 0.523 ± 0.131 |
| 44 | A067 | 48 | F | Pulmonary hypertension | 1.921 ± 0.689 | 0.263 ± 0.098 |
| 47 | A071 | 50 | M | Heart failure | 0.000 ± 0.000 | 0.000 ± 0.000 |
| 48 | A072 | 37 | M | Acute pancreatitis | 3.449 ± 1.018 | 0.756 ± 0.230 |
F: female; M: male; AA/WAA: percentage of APCC areas over the whole adrenal area; NOA: number of APCCs/mm2. Each value of AA/WAA and NOA by individual examiners and the characteristics of cases not used in statistical analyses are shown in Supplementary Figure 1.
Figure 1Double immunohistochemistry for CYP11B2 (blue) and CYP11B1 (brown). (a) Section A027 from Case 7; (b) section A024 from Case 4; (c) section A063 from Case 40; (d) section A063 from Case 40. These are enlarged images of frames in Supplementary Figure 1. Bars indicate 1 mm. Blue and red arrows indicate APCCs and pAATL, respectively.
Figure 2Relationship between age versus AA/WAA (%, (a)) and age versus NOA (APCCs/mm2, (b)). Error bars indicate SEM between 4 examiners (see Table 1 and Supplementary Table 1). Regression lines of females and males are drawn. AA/WAA: percentage of APCC areas over the whole adrenal area (%). NOA: number of APCCs/mm2.